WITHDRAWN

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.

Official Title

Evaluation of a Claims-based Algorithm for the Identification of ATTR Amyloidosis in Medical Records

Quick Facts

Study Start:2022-08-01

Study Completion:2025-02-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:WITHDRAWN

Study ID

NCT04569903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Identified by the ATTR diagnostic algorithm and matched by Yale's list of potential subjects defined as: 1. subjects within the claims dataset that are predicted to be at risk of having ATTR who are also being managed within YNHHS 2. patients who need to be contacted and offered additional clinical evaluation to determine whether they have a diagnosis of ATTR (non-hereditary or Hereditary ATTR amyloidosis).	* Patients who have opted out of research in the Epic system will be excluded entirely from the study * Patients who are pregnant or who may become pregnant

Inclusion Criteria

Exclusion Criteria

* Identified by the ATTR diagnostic algorithm and matched by Yale's list of potential subjects defined as:
1. subjects within the claims dataset that are predicted to be at risk of having ATTR who are also being managed within YNHHS
2. patients who need to be contacted and offered additional clinical evaluation to determine whether they have a diagnosis of ATTR (non-hereditary or Hereditary ATTR amyloidosis).

* Patients who have opted out of research in the Epic system will be excluded entirely from the study
* Patients who are pregnant or who may become pregnant

Contacts and Locations

Principal Investigator

Edward Miller, MD

PRINCIPAL_INVESTIGATOR

Yale University

Study Locations (Sites)

Yale New Haven Hospital

New Haven, Connecticut, 06520

United States

Collaborators and Investigators

Sponsor: Yale University

Edward Miller, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-01

Study Completion Date2025-02-01

Study Record Updates

Study Start Date2022-08-01

Study Completion Date2025-02-01

Terms related to this study

Additional Relevant MeSH Terms

Transthyretin Amyloidosis